Hans Nijman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3267568/publications.pdf

Version: 2024-02-01

113 papers	7,632 citations	101384 36 h-index	56606 83 g-index
118 all docs	118 docs citations	118 times ranked	9926 citing authors

#	Article	IF	Citations
1	The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. British Journal of Cancer, 2011, 105, 93-103.	2.9	1,045
2	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancerâ€"Combined Analysis of the PORTEC Cohorts. Clinical Cancer Research, 2016, 22, 4215-4224.	3.2	535
3	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 295-309.	5.1	426
4	Tumor-infiltrating lymphocytes in the immunotherapy era. Cellular and Molecular Immunology, 2021, 18, 842-859.	4.8	403
5	Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunology, Immunotherapy, 2009, 58, 449-459.	2.0	347
6	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Modern Pathology, 2015, 28, 836-844.	2.9	343
7	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology, The, 2019, 20, 1273-1285.	5.1	305
8	Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial. Journal of Clinical Oncology, 2009, 27, 3547-3556.	0.8	253
9	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research, 2015, 21, 3347-3355.	3.2	249
10	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	3.7	227
11	Myeloid derived suppressor cellsâ€"An overview of combat strategies to increase immunotherapy efficacy. OncoImmunology, 2015, 4, e954829.	2.1	219
12	Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecologic Oncology, 2009, 114, 105-110.	0.6	177
13	Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. British Journal of Cancer, 2018, 119, 1067-1074.	2.9	171
14	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. Cancer Immunology Research, 2019, 7, 784-796.	1.6	141
15	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 1114-1126.	5.1	135
16	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 2002-2007.	1.2	135
17	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clinical Cancer Research, 2016, 22, 2342-2350.	3.2	132
18	CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. European Journal of Cancer, 2016, 60, 1-11.	1.3	125

#	Article	IF	Citations
19	From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors. Clinical and Developmental Immunology, 2011, 2011, 1-15.	3.3	123
20	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. OncoImmunology, 2017, 6, e1338230.	2.1	116
21	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565.	2.1	102
22	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 797-809.	0.4	96
23	Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. OncoImmunology, 2015, 4, e989764.	2.1	95
24	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Science Translational Medicine, 2020, 12, .	5.8	83
25	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Modern Pathology, 2016, 29, 174-181.	2.9	68
26	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRÎ±Î²+ CD8Î±Î²+ T cells that can be targeted for cancer immunotherapy. Oncotarget, 2016, 7, 75130-75144.	0.8	64
27	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget, 2015, 6, 32228-32243.	0.8	58
28	Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review. European Journal of Cancer, 2020, 133, 14-21.	1.3	55
29	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. Modern Pathology, 2017, 30, 459-468.	2.9	53
30	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2016, 22, 714-724.	3.2	51
31	Noninvasive monitoring of cancer therapy induced activated T cells using [¹⁸F]FB-IL-2 PET imaging. OncoImmunology, 2017, 6, e1248014.	2.1	51
32	Addition of interferonâ€Î± to the p53â€SLPÂ® vaccine results in increased production of interferonâ€Î³ in vaccinated colorectal cancer patients: A phase I/II clinical trial. International Journal of Cancer, 2013, 132, 1581-1591.	2.3	50
33	First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. Molecular Therapy, 2021, 29, 611-625.	3.7	48
34	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, 13, 1373.	5.8	47
35	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	1.6	45
36	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clinical Cancer Research, 2020, 26, 5400-5410.	3.2	41

#	Article	IF	Citations
37	Whole Genome Analysis of Ovarian Granulosa Cell Tumors Reveals Tumor Heterogeneity and a High-Grade TP53-Specific Subgroup. Cancers, 2020, 12, 1308.	1.7	41
38	Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival. Oncotarget, 2016, 7, 18573-18584.	0.8	40
39	Therapeutic immunization and local lowâ€dose tumor irradiation, a reinforcing combination. International Journal of Cancer, 2014, 134, 859-872.	2.3	38
40	Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. OncoImmunology, 2018, 7, e1487913.	2.1	36
41	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. Modern Pathology, 2018, 31, 1851-1861.	2.9	35
42	Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. British Journal of Cancer, 2014, 110, 1535-1544.	2.9	30
43	Alphavirus-based Vaccines Encoding Nonstructural Proteins of Hepatitis C Virus Induce Robust and Protective T-cell Responses. Molecular Therapy, 2014, 22, 881-890.	3.7	30
44	Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. ACS Medicinal Chemistry Letters, 2021, 12, 768-773.	1.3	30
45	Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes. Vaccines, 2015, 3, 203-220.	2.1	29
46	Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. Oncotarget, 2016, 7, 39885-39893.	0.8	29
47	Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. OncoImmunology, 2014, 3, e962397.	2.1	27
48	Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands. Gynecologic Oncology, 2016, 141, 524-530.	0.6	27
49	Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression. Journal of Immunotherapy, 2011, 34, 516-523.	1.2	25
50	A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. OncoImmunology, 2015, 4, e1029699.	2.1	23
51	Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.. Journal of Clinical Oncology, 2017, 35, 5502-5502.	0.8	23
52	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget, 2017, 8, 84579-84594.	0.8	23
53	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. British Journal of Cancer, 2015, 113, 786-793.	2.9	20
54	Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 975-986.	0.4	20

#	Article	IF	Citations
55	Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition. Gene Therapy, 2008, 15, 393-403.	2.3	19
56	Heterologous Prime-Boost Immunizations with a Virosomal and an Alphavirus Replicon Vaccine. Molecular Pharmaceutics, 2011, 8, 65-77.	2.3	18
57	Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial. BMC Cancer, 2017, 17, 110.	1.1	18
58	Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. Gynecologic Oncology, 2018, 148, 56-61.	0.6	18
59	Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Therapy, 2015, 22, 560-567.	2.3	17
60	CD20⁺T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. OncoImmunology, 2015, 4, e999536.	2.1	17
61	Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antiviral Therapy, 2011, 16, 207-218.	0.6	16
62	Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. Oncology, 2018, 95, 100-108.	0.9	15
63	Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7. Vaccines, 2015, 3, 221-238.	2.1	14
64	TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial. BMC Cancer, 2016, 16, 132.	1.1	14
65	Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients. Gynecologic Oncology, 2017, 146, 380-385.	0.6	14
66	Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis â€“ A review. Cancer Treatment Reviews, 2022, 102, 102311.	3.4	14
67	Cervical cancer with â‰¥5 mm depth of invasion and >7 mm horizontal spread â€” Is lymph node assessment only required in patients with LVSI?. Gynecologic Oncology, 2020, 158, 282-286.	0.6	13
68	Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer. International Journal of Molecular Sciences, 2020, 21, 3770.	1.8	13
69	Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study. Journal of Immunotherapy, 2022, 45, 180-186.	1.2	13
70	HPV-Specific Immunotherapy: Key Role for Immunomodulators. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 265-279.	0.9	12
71	Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 112, 390-399.	0.4	12
72	Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. OncoImmunology, 2020, 9, 1760705.	2.1	11

#	Article	IF	Citations
73	Shortâ€term surgical complications after radical hysterectomyâ€"A nationwide cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 925-932.	1.3	11
74	FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring. Gynecologic Oncology, 2021, 162, 413-420.	0.6	11
75	Association of homozygous variants of STING1 with outcome in human cervical cancer. Cancer Science, 2021, 112, 61-71.	1.7	11
76	Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine, 2010, 28, 4275-4282.	1.7	10
77	Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer. Investigational New Drugs, 2020, 38, 1454-1462.	1.2	10
78	Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients. OncoImmunology, 2021, 10, 1935104.	2.1	10
79	L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelialâ€"mesenchymal transition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 591-598.	1.4	9
80	Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer. OncoImmunology, 2021, 10, 1936391.	2.1	9
81	Frozen section diagnosis of borderline ovarian tumors with suspicious features of invasive cancer is a devilâ€™s dilemma for the surgeon: A systematic review and metaâ€analysis. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1369-1376.	1.3	9
82	Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?. Current Opinion in Oncology, 2017, 29, 351-358.	1.1	8
83	The impact of centralization of services on treatment delay in ovarian cancer: A study on process quality. International Journal for Quality in Health Care, 2017, 29, 810-816.	0.9	8
84	Implementation of laparoscopic hysterectomy for endometrial cancer over the past decade. Gynecological Surgery, 2018, 15, 7.	0.9	8
85	GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles. European Journal of Pharmaceutical Sciences, 2020, 143, 105096.	1.9	8
86	In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors. Cancers, 2021, 13, 368.	1.7	8
87	Automated causal inference in application to randomized controlled clinical trials. Nature Machine Intelligence, 2022, 4, 436-444.	8.3	8
88	Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification. European Journal of Cancer, 2017, 78, 82-90.	1.3	6
89	Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study. BMC Public Health, 2018, 18, 837.	1.2	6
90	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells, 2019, 8, 200.	1.8	6

#	Article	IF	Citations
91	Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET. Molecular Imaging and Biology, 2020, 22, 883-890.	1.3	6
92	Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival.. Journal of Clinical Oncology, 2017, 35, 5525-5525.	0.8	6
93	397â€...Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial â€“ prognostic refinement and druggable targets. , 2021, , .		6
94	No improvement in survival of older women with cervical cancerâ€"A nationwide study. European Journal of Cancer, 2021, 151, 159-167.	1.3	5
95	Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas. Oncotarget, 2016, 7, 26192-26205.	0.8	5
96	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. Cancers, 2022, 14, 1924.	1.7	5
97	Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer. International Journal of Gynecological Cancer, 2019, 29, 392-397.	1.2	4
98	Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer.. Journal of Clinical Oncology, 2017, 35, 140-140.	0.8	4
99	595â€...Implementation of collaborative translational research (TransPORTEC) findings in an international endometrial cancer clinical trials program (RAINBO). , 2021, , .		4
100	STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.. Journal of Clinical Oncology, 2018, 36, TPS5615-TPS5615.	0.8	3
101	Size matters: Survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation. OncoImmunology, 2016, 5, e1122863.	2.1	2
102	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.. Journal of Clinical Oncology, 2015, 33, 5501-5501.	0.8	2
103	Borderline ovarian tumor frozen section diagnoses with features suspicious of invasive cancer: a retrospective study. Journal of Ovarian Research, 2021, 14, 139.	1.3	2
104	Vaginal hysterectomy with or without bilateral salpingo-oophorectomy may be an alternative treatment for endometrial cancer patients with medical co-morbidities precluding standard surgical procedures: a systematic review. International Journal of Gynecological Cancer, 2019, 29, 299-304.	1.2	1
105	Prognostic relevance of the molecular classification in high-risk endometrial cancer: analysis of the PORTEC-3 trial. , 2019, , .		1
106	Borderline tumours of the ovary: Common practice in the Netherlands. Gynecologic Oncology Reports, 2019, 27, 25-30.	0.3	1
107	EP1121â€...The clinical potential ofFOXL2c.402C>G mutation detection in circulating tumour DNA of patients with granulosa cell tumours. , 2019, , .		1
108	482â€...Tertiary lymphoid structures as markers of anti-tumor immunity with independent prognostic value in the PORTEC-3 trial of high-risk endometrial cancer. , 2021, , .		0

#	Article	IF	Citations
109	EP824â€…Ambiguous diagnoses of borderline ovarian tumors at frozen section with a definite diagnosis of invasive carcinoma: consequences for counseling and perioperative treatment. , 2019, , .		0
110	Whole genome sequencing of ovarian granulosa cell tumours show heterogeneity, genomic instability and tumour evolution. , 2019, , .		0
111	171â€…Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer. , 2020, , .		0
112	Rapid and efficient generation of antigenâ€specific isogenic T cells from cryopreserved blood samples. Immunology and Cell Biology, 2022, 100, 285-295.	1.0	0
113	End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.. Journal of Clinical Oncology, 2022, 40, e17612-e17612.	0.8	0